antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»10.37489/0235-2990-2021-66-7-8-4-12antibiotics-834Research ArticleЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯEXPERIMENTAL STUDIESПодход к поиску продуцентов антибиотиков, преодолевающих лекарственную устойчивость микроорганизмовApproach to Searching for the Producers of Antibiotics That Overcome Drug Resistance of MicroorganismsДемьянковаМ. В.DemiankovaM. V.

Демьянкова Мария Владимировна — м. н. с.

Москва

Mariya V. Demiankova — Junior Researcher

Moscow

СадыковаВ. С.SadykovaV. S.

Садыкова Вера Сергеевна — зав. лаб. таксономического изучения и коллекции культур микроорганизмов, зам. директора

Москва

Vera S. Sadykova — Head of the Laboratory of Taxonomic Study and Collection of Microorganism Cultures, Deputy Director

Moscow

ГлуховаА. А.GlukhovaA. A.

Глухова Алла Алексеевна — н. с.

Москва

Alla A. Glukhova — Researcher

Moscow

ЕфименкоТ. А.EfimenkoT. A.

Ефименко Татьяна Александровна — с. н. с.

Москва

Tatiana A. Efimenko — Senior Researcher

Moscow

БойковаЮ. В.BoykovaYu. V.

Бойкова Юлия Вадимовна — н. с.

Москва

Yuliya V. Boykova — Researcher

Moscow

МалкинаН. Д.MalkinaN. D.

Малкина Наталия Дмитриевна — н. с.

Natalia D. Malkina — Researcher

Moscow

КормилицинаВ. Г.KormilitsinaV. G.

Кормилицина Виктория Георгивна — лаборант-исследователь

Москва

Victoria G. Kormilitsina — Laboratory Assistant-Researcher

Moscow

ШарапченкоС. О.SharapchenkoS. O.

Шарапченко Софья Олеговна — лаборант-исследователь

Москва

Sofya O. Sharapchenko — Laboratory Assistant-Researcher

Moscow

СумаруковаИ. Г.SumarukovaI. G.

Сумарукова Ирина Георгиевна — н. с.

Москва

Irina G. Sumarukova — Researcher

Moscow

ВасильеваБ. Ф.VasilievaB. F.

Васильева Бязиля Ф. — н. с.

Москва

Byazilya F. Vasilieva — Researcher

Moscow

ИванковаТ. Д.IvankovaT. D.

Иванкова Татьяна Дмитриевна — м. н. с.

Москва

Tatiana D. Ivankova — Junior Researcher

Moscow

ТереховаЛ. П.TerekhovaL. P.

Терехова Лариса Петровна — ведущий научный сотрудник

Москва

Larissa P. Terekhova — Leading Researcher

Moscow

ГабриэлянН. И.GabrielyanN. I.

Габриэлян Нина Индзаровна — заведующая отделом

Москва

Nina I. Gabrielyan — Head of Department

Moscow

ЕфременковаО. В.EfremenkovaO. V.

Ефременкова Ольга Владимировна — заведующий сектора

Большая Пироговская улица, 11, стр. 1, г. Москва, 119021

Olga V. Efremenkova — Head of the Sector

11/1 Bolshaya Pirogovskaya st., Moscow, 119021

mary_bunny@mail.ruФГБНУ «Научно-исследовательский институт по изысканию новых антибиотиков им. Г. Ф. Гаузе»; ФГБУ «Федеральный научный центр трансплантологии и искусственных органов им. академика В. И. Шумакова» Минздрава РоссииРоссияGause Institute of New Antibiotics; Academician V. I. Shumakov Federal Research Center of Transplantology and Artificial OrgansRussian FederationФГБНУ «Научно-исследовательский институт по изысканию новых антибиотиков им. Г. Ф. Гаузе»РоссияGause Institute of New AntibioticsRussian FederationФГБУ «Федеральный научный центр трансплантологии и искусственных органов им. академика В. И. Шумакова» Минздрава РоссииРоссияAcademician V. I. Shumakov Federal Research Center of Transplantology and Artificial OrgansRussian Federation202120102021667-8412Copyright © ООО «Издательство ОКИ», 20212021ООО «Издательство ОКИ»ООО «Издательство ОКИ»https://www.antibiotics-chemotherapy.ru/jour/about/submissions#copyrightNoticehttps://www.antibiotics-chemotherapy.ru/jour/article/view/834

В настоящее время проблема устойчивости к антибиотикам оппортунистических и патогенных микроорганизмов является чрезвычайно актуальной. Чтобы найти новые эффективные природные антибиотики, необходимо активизировать процесс поиска. При поэтапном отборе наиболее перспективных продуцентов нами была введена стадия определения антибиотической активности культуральной жидкости исследуемых природных штаммов в отношении клинических изолятов госпитальных микроорганизмов с множественной устойчивостью к антибиотикам медицинского назначения. Определение видовой принадлежности потенциальных продуцентов позволяет выбрать тех продуцентов конкретного вида, которые отличаются по антимикробному спектру активности от описанных в литературе. Были отобраны четыре штамма актиномицетов, которые проявляли активность в отношении устойчивых клинических изолятов дрожжей Candida albicans, C.famata, C. arapsilosis и Cryptococcus neoformans, а именно: Nocardia soli ИНА 01217, Streptomyces bottropensis ИНА 01214, S.chromofuscus ИНА 01211 и S.netropsis ИНА 01190. Штамм N.soli ИНА 01217 также проявляет антибиотическую активность против грамотрицательной бактерии Escherichia coli ATCC 25922. Эти штаммы продуцентов актиномицетов были отобраны для последующих химических исследований образованных ими противомикробных соединений.

Currently, the problem of antibiotic resistance of opportunistic and pathogenic microorganisms is extremely urgent. In order to find new effective natural antibiotics, it is necessary to intensify the search process. In the gradual selection of the most promising producers, we introduced the stage of determining the antibiotic activity of the culture fluid of the studied natural strains against the clinical isolates of hospital microorganisms with multiple resistance to medical antibiotics. Determining the species affiliation of potential producers allows to select those producers of a particular species that differ in the antimicrobial spectrum of activity from those described in the literature. Four strains of actinomycetes that showed activity against resistant clinical isolates of yeast Candida albicans, C.famata, C.parapsilosis and Cryptococcus neoformans were selected, namely: Nocardia soli INA 01217, Streptomyces bottropensis INA 01214, S.chromofuscus INA 01211 and S.netropsis INA 01190. The N.soli INA 01217 strain also shows antibiotic activity against the Gram-negative bacterium Escherichia coli ATCC 25922. These strains of actinobacterial producers were selected for subsequent chemical studies of the antimicrobial compounds formed by them.

устойчивость к антибиотикампоиск антибиотиковпротивогрибковыеактиномицетыantibiotic resistancesearching for antibioticsantimycoticsactinobacteriaReferencesCenters for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Available online: http://www.cdc.gov/drugresistance/threat-report-2013.Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Available online: http://www.cdc.gov/drugresistance/threat-report-2013.O’Neill J. The Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: Final report and recommendations, 2016. Available online: http://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf.O’Neill J. The Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: Final report and recommendations, 2016. Available online: http://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf.Berdy J. Thoughts and facts about antibiotics: Where we are now and where we are heading. J Antibiot. 2012; 65: 385–395.Berdy J. Thoughts and facts about antibiotics: Where we are now and where we are heading. J Antibiot. 2012; 65: 385–395.Ефименко Т.А.; Терехова Л.П.; Ефременкова O.В. Современное состояние проблемы антибиотикорезистентности патогенных бактерий. Анибиотики и химиотер. 2019; 64: 5–6, 64–68.Efimenko Т.А., Terekhova L.P., Efremenkova O.V. Current state the problem of antibiotic resistance of pathogens. Antibiotiki i Khimioter. 2019; 64 (5-6): 64–68. (in Russian)Glukhova A.A., Karabanova A.A., Yakushev A.V., Semenyuk I.I., Boykova Y.V., Malkina N.D., Efimenko T.A., Ivankova T.D., Terekhova L.P., Efremenkova O.V. Antibiotic Activity of Actinobacteria from Digestive Tract of Millipede Nedyopus dawydoffiae (Diplopoda). Antibiotics (Basel). 2018; 7: 4: 94. doi: 10.3390/antibiotics7040094.Glukhova A.A., Karabanova A.A., Yakushev A.V., Semenyuk I.I., Boykova Y.V., Malkina N.D., Efimenko T.A., Ivankova T.D., Terekhova L.P., Efremenkova O.V. Antibiotic Activity of Actinobacteria from Digestive Tract of Millipede Nedyopus dawydoffiae (Diplopoda). Antibiotics (Basel). 2018; 7: 4: 94. doi: 10.3390/antibiotics7040094.Valagurova E.V., Kozyritskaya V.E., Iutinskaya G.A. Actinomycetes of Streptomyces genus. (in Russian) Publisher «Scientific Book»: Kiev, Ukraine, 2003; 1–645.Valagurova E.V., Kozyritskaya V.E., Iutinskaya G.A. Actinomycetes of Streptomyces genus. (in Russian) Publisher «Scientific Book»: Kiev, Ukraine, 2003; 1–645.Goodfellow M., Kämpfer P., Busse H.-J., Suzuki K., Ludwig W., Whitman W.B. (eds.). Bergey’s manual of systematic bacteriology, 2 nd ed.; Springer-Verlag, New York, USA; 2012; 5: A: 376–419, 1455–1768.Goodfellow M., Kämpfer P., Busse H.-J., Suzuki K., Ludwig W., Whitman W.B. (eds.). Bergey’s manual of systematic bacteriology, 2 nd ed.; Springer-Verlag, New York, USA; 2012; 5: A: 376–419, 1455–1768.Demiankova M.V., Kalashnikova E.A., Glukhova A.A., Ivankova T.D., Terekhova L.P., Boykova Y.V., Efimenko T.A., Efremenkova O.V. Activity of the strain Streptomyces hydrogenans against phytopathogenic fungi. Open Acc J Envi Soi Sci (OAJESS). 2018; 1: 5:103–105, doi:10.32474/OA-JESS.2018.01.000121.Demiankova M.V., Kalashnikova E.A., Glukhova A.A., Ivankova T.D., Terekhova L.P., Boykova Y.V., Efimenko T.A., Efremenkova O.V. Activity of the strain Streptomyces hydrogenans against phytopathogenic fungi. Open Acc J Envi Soi Sci (OAJESS). 2018; 1: 5:103–105, doi:10.32474/OA-JESS.2018.01.000121.Brown M.S., Akopiants K., Resceck D.M., McArthur H.A.I., McCormick E., Reynolds K.A. Biosynthetic Origins of the natural product, thiolactomycin: A unique and selective inhibitor of type II dissociated fatty acid synthases. J Am Chem Soc. 2003; 125 (34): 10166–10167. doi: 10.1021/ja034540i.Brown M.S., Akopiants K., Resceck D.M., McArthur H.A.I., McCormick E., Reynolds K.A. Biosynthetic Origins of the natural product, thiolactomycin: A unique and selective inhibitor of type II dissociated fatty acid synthases. J Am Chem Soc. 2003; 125 (34): 10166–10167. doi: 10.1021/ja034540i.Fulmer T. Fatty acid synthase II (FASII) pathway. Science-Business eXchange 2009, 2, 11, 430–430. doi: 10.1038/scibx.2009.430.Fulmer T. Fatty acid synthase II (FASII) pathway. Science-Business eXchange 2009, 2, 11, 430–430. doi: 10.1038/scibx.2009.430.Tatsuta K., Gunji H., Tajima S., Ishiyama T., Imai S., Okuyama S., Fukatsu S. Biosynthetic studies on oleandomycin by incorporation of the chemically synthesized aglycones. J Antibiot. 1990; 43: 909–911. doi: 10.7164/antibiotics.43.909.Tatsuta K., Gunji H., Tajima S., Ishiyama T., Imai S., Okuyama S., Fukatsu S. Biosynthetic studies on oleandomycin by incorporation of the chemically synthesized aglycones. J Antibiot. 1990; 43: 909–911. doi: 10.7164/antibiotics.43.909.Vilches C., Hernandez C., Mendez C., Salas J.A. Role of glycosylation and deglycosylation in biosynthesis of and resistance to oleandomycin in the producer organism, Streptomyces antibioticus. J Bact. 1992; 174: 1: 161–165. doi: 10.1128/jb.174.1.161-165.1992.Vilches C., Hernandez C., Mendez C., Salas J.A. Role of glycosylation and deglycosylation in biosynthesis of and resistance to oleandomycin in the producer organism, Streptomyces antibioticus. J Bact. 1992; 174: 1: 161–165. doi: 10.1128/jb.174.1.161-165.1992.Schimana J., Fiedler H.-P., Groth I., Submuth R., Beil W., Walker M., Zeeck A. Simocyclinones, novel cytostatic angucyclinone antibiotics produced by Streptomyces antibioticus Tü 6040. I. Taxonomy, fermentation, isolation and biological activities. J Antibiot. 2000; 53 (8): 779–787. doi: 10.7164/antibiotics.53.779.Schimana J., Fiedler H.-P., Groth I., Submuth R., Beil W., Walker M., Zeeck A. Simocyclinones, novel cytostatic angucyclinone antibiotics produced by Streptomyces antibioticus Tü 6040. I. Taxonomy, fermentation, isolation and biological activities. J Antibiot. 2000; 53 (8): 779–787. doi: 10.7164/antibiotics.53.779.Hollstein U. Actinomycin. Chemistry and mechanism of action. Chem Rev. 1974; 74 (6): 625–652. doi: 10.1021/cr60292a002.Hollstein U. Actinomycin. Chemistry and mechanism of action. Chem Rev. 1974; 74 (6): 625–652. doi: 10.1021/cr60292a002.Hütter R., Keller-Schierlein W., Knüsel F., Prelog V., Rodgers G. C. The metabolic products of microorganisms. Boromycin. Helvetica Chimica Acta. 1967; 50 (6): 1533–1539Hütter R., Keller-Schierlein W., Knüsel F., Prelog V., Rodgers G. C. The metabolic products of microorganisms. Boromycin. Helvetica Chimica Acta. 1967; 50 (6): 1533–1539Waisvisz J.M., van der Hoeven M.G., van Peppen J., Zwennis W.C.M. Bottromycin. I. A new sulfur-containing antibiotic. J Am Chem Soc. 1957; 79 (16): 4520–4521. doi: 10.1021/ja01573a072.Waisvisz J.M., van der Hoeven M.G., van Peppen J., Zwennis W.C.M. Bottromycin. I. A new sulfur-containing antibiotic. J Am Chem Soc. 1957; 79 (16): 4520–4521. doi: 10.1021/ja01573a072.Yamazaki M., Yamashita T., Harada T., Nishikiori T., Saito S., Shimada N., Fujii A. 44-Homooligomycins A and B, new anti-tumor antibiotics from Streptomyces bottropensis producing organisms, fermentation, isolation, structure elucidation and biological properties. J Antibiot. 1992; 45 (2): 171–179. doi: 10.7164/antibiotics.45.171.Yamazaki M., Yamashita T., Harada T., Nishikiori T., Saito S., Shimada N., Fujii A. 44-Homooligomycins A and B, new anti-tumor antibiotics from Streptomyces bottropensis producing organisms, fermentation, isolation, structure elucidation and biological properties. J Antibiot. 1992; 45 (2): 171–179. doi: 10.7164/antibiotics.45.171.Leach B.E., Calhoun K.M., Johnson LeRoy E., Teeters C.M., Jackson W.G. Char-treusin, a new antibiotic produced by Streptomyces chartreusis, a new species. J Am Chem Soc. 1953; 75 (16): 4011–4012. doi: 10.1021/ja01112a040.Leach B.E., Calhoun K.M., Johnson LeRoy E., Teeters C.M., Jackson W.G. Char-treusin, a new antibiotic produced by Streptomyces chartreusis, a new species. J Am Chem Soc. 1953; 75 (16): 4011–4012. doi: 10.1021/ja01112a040.Wu Q., Liang J., Lin S., Zhou X., Bai L., Deng Z., Wang Z. Characterization of the biosynthesis gene cluster for the pyrrole polyether antibiotic calcimycin (A23187) in Streptomyces chartreusis NRRL 3882. Antim Agent Chem. 2011; 55 (3): 974–982. doi: 10.1128/AAC.01130-10.Wu Q., Liang J., Lin S., Zhou X., Bai L., Deng Z., Wang Z. Characterization of the biosynthesis gene cluster for the pyrrole polyether antibiotic calcimycin (A23187) in Streptomyces chartreusis NRRL 3882. Antim Agent Chem. 2011; 55 (3): 974–982. doi: 10.1128/AAC.01130-10.Miller-Wideman M., Makkar N., Tran M., Isaac B., Biest N., Stonard R. Herboxidiene, a new herbicidal substance from Streptomyces chromofuscus A7847. Taxonomy, fermentation, isolation, physico-chemical and biological properties. J Antibiot (Tokyo). 1992; 45 (6): 914–921. doi: 10.7164/antibiotics.45.914.Miller-Wideman M., Makkar N., Tran M., Isaac B., Biest N., Stonard R. Herboxidiene, a new herbicidal substance from Streptomyces chromofuscus A7847. Taxonomy, fermentation, isolation, physico-chemical and biological properties. J Antibiot (Tokyo). 1992; 45 (6): 914–921. doi: 10.7164/antibiotics.45.914.Fujiwara A., Tazoe M., Hoshino T., Sekine Y., Fujiwara M. Structural studies of an antracyclinone antibiotic SM-173B produced by Streptomyces chromofuscus SM-173. Symposium on the Chemistry of Natural Products, symposium papers. 1979; 22: Abstr. No. 59: 448–455.Fujiwara A., Tazoe M., Hoshino T., Sekine Y., Fujiwara M. Structural studies of an antracyclinone antibiotic SM-173B produced by Streptomyces chromofuscus SM-173. Symposium on the Chemistry of Natural Products, symposium papers. 1979; 22: Abstr. No. 59: 448–455.Akiko F., Mitsuhiko F., Tatsuo H., Yuzuru S., Masaaki T. Antibiotic SM-173B. Patent US 4206129, June 3, 1980.Akiko F., Mitsuhiko F., Tatsuo H., Yuzuru S., Masaaki T. Antibiotic SM-173B. Patent US 4206129, June 3, 1980.Kulkarni M., Gorthi S., Banerjee G., Chattopadhyay P. Production, characterization and optimization of actinomycin D from Streptomyces hydrogenans IB310, an antagonistic bacterium against phytopathogens. Biocatalysis and Agricultural Biotechnology, 2017, 10, 69-74. doi: 10.1016/j.bcab.2017.02.009.Kulkarni M., Gorthi S., Banerjee G., Chattopadhyay P. Production, characterization and optimization of actinomycin D from Streptomyces hydrogenans IB310, an antagonistic bacterium against phytopathogens. Biocatalysis and Agricultural Biotechnology, 2017, 10, 69-74. doi: 10.1016/j.bcab.2017.02.009.Hayashi T., Noto T., Nawata Y., Okazaki H., Sawada M., Ando K. Cyanocycline A, a new antibiotic. Taxonomy of the producing organism, fermentation, isolation and characterization. J Antibiot (Tokyo). 1982; 35 (7): 771–777. doi: 10.7164/antibiotics.35.771.Hayashi T., Noto T., Nawata Y., Okazaki H., Sawada M., Ando K. Cyanocycline A, a new antibiotic. Taxonomy of the producing organism, fermentation, isolation and characterization. J Antibiot (Tokyo). 1982; 35 (7): 771–777. doi: 10.7164/antibiotics.35.771.Gould S.J., He W., Cone M.C. New cyanocyclines from a cyanide-treated broth of Streptomyces lusitanus. J Nat Prod. 1993; 56 (8): 1239–1245. doi:10.1021/np50098a006.Gould S.J., He W., Cone M.C. New cyanocyclines from a cyanide-treated broth of Streptomyces lusitanus. J Nat Prod. 1993; 56 (8): 1239–1245. doi:10.1021/np50098a006.Kluepfel D., Baker H. A., Piattoni G., Sehgal S. N., Sidorowicz A., Singh K., Vezina C. Naphthyridinomycin, a new broad-spectrum antibiotic. J Antibiot (Tokyo). 1975; 28 (7): 497–502. doi: 10.7164/antibiotics.28.497.Kluepfel D., Baker H. A., Piattoni G., Sehgal S. N., Sidorowicz A., Singh K., Vezina C. Naphthyridinomycin, a new broad-spectrum antibiotic. J Antibiot (Tokyo). 1975; 28 (7): 497–502. doi: 10.7164/antibiotics.28.497.Villax I. Process of fermentation of chlortetracycline and tetracycline antibiotics. Patent US 3401088 A. Sept., 10, 1968.Villax I. Process of fermentation of chlortetracycline and tetracycline antibiotics. Patent US 3401088 A. Sept., 10, 1968.Han Z., Xu Y., McConnell O., Liu L., Li Y., Qi S., Huang X., Qian P. Two antimycin a analogues from marine-derived actinomycete Streptomyces lusitanus. Mar Drugs. 2012; 10 (3): 668–676. doi: 10.3390/md10030668.Han Z., Xu Y., McConnell O., Liu L., Li Y., Qi S., Huang X., Qian P. Two antimycin a analogues from marine-derived actinomycete Streptomyces lusitanus. Mar Drugs. 2012; 10 (3): 668–676. doi: 10.3390/md10030668.Finlay A.C., Hochstein F.A., Sobin B.A., Murphy F.X. Netropsin, a New antibiotic produced by a Streptomyces. J Am Chem Soc. 1951; 73 (1): 341–343. doi: 10.1021/ja01145a113.Finlay A.C., Hochstein F.A., Sobin B.A., Murphy F.X. Netropsin, a New antibiotic produced by a Streptomyces. J Am Chem Soc. 1951; 73 (1): 341–343. doi: 10.1021/ja01145a113.Arcamone F., Cassinelli G., Fantini G., Grein A., Orezzi P., Pol C., Spalla C. Adriamycin, 14-hydroxydaimomycin, a new antitumor antibiotic from S.peucetius var. caesius. Biothecnology and Bioengineering, 1969; 11 (6) 1101–1110. doi: 10.1002/bit.260110607.Arcamone F., Cassinelli G., Fantini G., Grein A., Orezzi P., Pol C., Spalla C. Adriamycin, 14-hydroxydaimomycin, a new antitumor antibiotic from S.peucetius var. caesius. Biothecnology and Bioengineering, 1969; 11 (6) 1101–1110. doi: 10.1002/bit.260110607.Grein A., Spalla C., Di Marco A., Canevazzi G. Descrizione e classificazione di un attinomiceti (Streptomyces peucetius sp. nova) produttore di una sostanza attivita antitumorale: La daunomicina. (in Italian) G Microbiol. 1963; 11: 109–118.Grein A., Spalla C., Di Marco A., Canevazzi G. Descrizione e classificazione di un attinomiceti (Streptomyces peucetius sp. nova) produttore di una sostanza attivita antitumorale: La daunomicina. (in Italian) G Microbiol. 1963; 11: 109–118.Guilfoile P.G., Hutchinson C.R. A bacterial analog of the mdr gene of mammalian tumor cells is present in Streptomyces peucetius, the producer of daunorubicin and doxorubicin. PNAS. 1991; 88 (19): 8553–8557. doi: 10.1073/pnas.88.19.8553.Guilfoile P.G., Hutchinson C.R. A bacterial analog of the mdr gene of mammalian tumor cells is present in Streptomyces peucetius, the producer of daunorubicin and doxorubicin. PNAS. 1991; 88 (19): 8553–8557. doi: 10.1073/pnas.88.19.8553.Boucher H.W., Talbot G.H., Bradley J.S., Edwards J.E., Gilbert D., Rice L.B., Scheld M., Spellberg B., Bartlett J. Bad bugs, no drugs: no ESKAPE! Clin Infect Dis. 2009; 48 (1): 1–12. doi: 10.1086/595011.Boucher H.W., Talbot G.H., Bradley J.S., Edwards J.E., Gilbert D., Rice L.B., Scheld M., Spellberg B., Bartlett J. Bad bugs, no drugs: no ESKAPE! Clin Infect Dis. 2009; 48 (1): 1–12. doi: 10.1086/595011.Tacconelli E., Magrini N., World Health Organisation. 2017, Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Available on line: https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25FebET_NM_WHO.pdfTacconelli E., Magrini N., World Health Organisation. 2017, Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Available on line: https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25FebET_NM_WHO.pdfBeardsley J., Halliday C.L., Chen S.C-A, Sorrell T.C. Responding to the emergence of antifungal drug resistance: perspectives from the bench and the bedside. Future Microbiol. 2018, 13, 10, 1175–1191. doi:10.2217/fmb-2018-0059.Beardsley J., Halliday C.L., Chen S.C-A, Sorrell T.C. Responding to the emergence of antifungal drug resistance: perspectives from the bench and the bedside. Future Microbiol. 2018, 13, 10, 1175–1191. doi:10.2217/fmb-2018-0059.Fisher M.C., Hawkins N.J., Sanglard D., Gurr S.J. Worldwide emergence of resistance to antifungal drugs challenges human health and food security. Science. 2018; 360 (6390): 739–742. doi: 10.1126/science.aap7999.Fisher M.C., Hawkins N.J., Sanglard D., Gurr S.J. Worldwide emergence of resistance to antifungal drugs challenges human health and food security. Science. 2018; 360 (6390): 739–742. doi: 10.1126/science.aap7999.Butler M.S., Cooper M.A. Antibiotics in the clinical pipeline in 2011. J Antibiot. 2011; 64 (6): 413–425. doi: 10.1038/ja.2011.44.Butler M.S., Cooper M.A. Antibiotics in the clinical pipeline in 2011. J Antibiot. 2011; 64 (6): 413–425. doi: 10.1038/ja.2011.44.Butler M.S., Blaskovich M.A., Cooper M.A. Antibiotics in the clinical pipeline in 2013. J Antibiot. 2013; 66 (10): 571–591. doi: 10.1038/ja.2013.86.Butler M.S., Blaskovich M.A., Cooper M.A. Antibiotics in the clinical pipeline in 2013. J Antibiot. 2013; 66 (10): 571–591. doi: 10.1038/ja.2013.86.Butler M.S., Blaskovich M.A., Cooper M.A. Antibiotics in the clinical pipeline at the end of 2015. J Antibiot. 2017; 70 (1): 3–24. doi:10.1038/ja.2016.72.Butler M.S., Blaskovich M.A., Cooper M.A. Antibiotics in the clinical pipeline at the end of 2015. J Antibiot. 2017; 70 (1): 3–24. doi:10.1038/ja.2016.72.Berdy J. Bioactive microbial metabolites. J Antibiot. 2005; 58 (1): 1–26. doi: 10.1038/ja.2005.Berdy J. Bioactive microbial metabolites. J Antibiot. 2005; 58 (1): 1–26. doi: 10.1038/ja.2005.Baltz R.H. Marcel Faber Roundtable: is our antibiotic pipeline unproductive because of starvation, constipation or lack of inspiration? J Ind Microbiol Biotechnol. 2006; 33 (7): 507–513. doi: 10.1007/s10295-005-0077-9.Baltz R.H. Marcel Faber Roundtable: is our antibiotic pipeline unproductive because of starvation, constipation or lack of inspiration? J Ind Microbiol Biotechnol. 2006; 33 (7): 507–513. doi: 10.1007/s10295-005-0077-9.

The authors declare that there are no conflicts of interest present.